Browsing by Author Gray, Alastair

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 8 of 8
Issue DateTitleAuthor(s)Citation
2008Cost effectiveness of self monitoring of blood glucose in patients with non-insulin treated type 2 diabetes: economic evaluation of data from the DiGEM trialClarke, Philip; Farmer, Andrew; Gray, Alastair; Neil, Andrew; Simon, Judit; Wade, Alisha; School of Public Health: Public HealthCost effectiveness of self monitoring of blood glucose in patients with non-insulin treated type 2 diabetes: economic evaluation of data from the DiGEM trial, British Medical Journal, vol.336,(7654),2008,pp 1177-1180
2008Development of life-expectancy tables for people with type 2 diabetesClarke, Philip; Gray, Alastair; Leal, Jose; School of Public Health: Public HealthDevelopment of life-expectancy tables for people with type 2 diabetes, European Heart Journal, vol.doi:10.1093/eurheartj/ehn567, N/A, 2008,pp 1-6
2008The economic analyses of the UK prospective diabetes studyScolyer, Richard; Gray, Alastair; Central Clinical School: PathologyThe economic analyses of the UK prospective diabetes study, Diabetic Medicine, vol.25, Suppl. 2, 2008,pp 47-57
2012The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trialsKeech, Anthony (Tony); Simes, Robert John; Baigent, C; Barnes, Elizabeth; Blackwell, L; Braunwald, Eugene; Collins, Rory; de Lemos, James A; Emberson, Jonathan; et al, Various; Gray, Alastair; Mihaylova, Borislava; Voysey, M; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials CentreThe effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials, The Lancet, vol.380, 9841, 2012,pp 581-590
2016The impact of social disadvantage in moderate-to-severe chronic kidney disease: an equity-focused systematic reviewMorton, Rachael; Cass, Alan; Gray, Alastair; Mihaylova, Borislava; Schlackow, Iryna; Staplin, Natalie D; NH&MRC Clinical Trials CentreThe impact of social disadvantage in moderate-to-severe chronic kidney disease: an equity-focused systematic review, Nephrology, Dialysis, Transplantation, vol.31, 1, 2016,pp 46-56
2013Temporal Validation of the UKPDS Outcomes Model Using 10-Year Posttrial Monitoring DataHayes, Alison; Clarke, Philip M; Gray, Alastair; Holman, Rury R.; Leal, Jose; School of Public Health: Public HealthTemporal Validation of the UKPDS Outcomes Model Using 10-Year Posttrial Monitoring Data, Diabetes Care, vol.36, 6, 2013,pp 1541-1546
2013UKPDS Outcomes Model 2: a new version of a model to simulate lifetime health outcomes of patients with type 2 diabetes mellitus using data from the 30 year United Kingdom Prospective Diabetes Study: UKPDS 82Hayes, Alison; Clarke, Philip M; Gray, Alastair; Holman, R.R.; Leal, Jose; School of Public Health: Public HealthUKPDS Outcomes Model 2: a new version of a model to simulate lifetime health outcomes of patients with type 2 diabetes mellitus using data from the 30 year United Kingdom Prospective Diabetes Study: UKPDS 82, Diabetologia: clinical and experimental diabetes and metabolism, vol.56, 9, 2013,pp 1925-1933
2015What is the impact of chronic kidney disease stage and cardiovascular disease on the annual cost of hospital care in moderate-to-severe kidney disease?Cass, Alan; Baigent, C; Emberson, Jonathan; Gray, Alastair; Haynes, Richard; Herrington, William; Kent, Seamus; Landray, Martin J.; Lozano-Kuhne, Jingky; Mihaylova, Borislava; Reith, Christiana; Schlackow, Iryna; School of Public Health: MedicineWhat is the impact of chronic kidney disease stage and cardiovascular disease on the annual cost of hospital care in moderate-to-severe kidney disease?, BMC Nephrology, vol.16, 1, 2015,pp 1-8